Protara therapeutics, inc. (PRTO)
Income statement / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Sep'13
Revenue

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

Operating expense:
Research & development

8,424

6,438

6,066

8,214

8,854

11,848

12,398

20,380

21,511

21,686

22,910

17,416

18,766

18,869

18,012

16,248

14,097

12,381

10,675

9,370

7,876

6,432

5,529

0

0

0

General & administrative

15,460

8,816

7,823

8,706

7,680

9,524

9,179

8,881

8,736

8,676

8,728

9,082

9,600

9,836

10,014

9,694

8,972

8,489

7,281

6,318

5,339

4,096

3,640

0

0

0

Total operating expenses

23,885

15,254

13,890

16,921

16,535

21,372

21,577

29,261

30,247

30,362

31,638

26,498

28,366

28,705

28,026

25,942

23,069

20,870

17,956

15,688

13,215

10,528

9,169

0

0

0

Operating loss

-23,885

-15,254

-13,890

-16,921

-16,535

-21,372

-21,577

-29,261

-30,247

-30,362

-31,638

-26,498

-28,366

-28,705

-28,026

-25,942

-23,069

-20,870

-17,956

-12,740

-10,267

-7,580

-6,221

0

0

0

Other (income) expense, net
Interest (income) expense, net

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Investment income

-

-

356

416

-

436

409

379

319

259

199

162

169

193

188

176

160

144

121

90

0

-

0

0

-

-

Interest expense

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

Interest expense

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

Other income, net

-

-

2

-1

-

207

147

64

381

139

64

161

-275

-14

-68

-416

-440

-651

10,032

5,042

5,141

5,071

-5,613

0

0

0

Total other (income) expense, net

0

-

358

415

-

643

556

443

700

398

263

323

-106

179

120

-240

-280

-507

10,154

5,140

5,176

4,238

-6,286

0

0

0

Net Loss

-23,524

-14,992

-13,638

-16,612

-16,176

-20,729

-21,021

-28,818

-29,547

-29,964

-31,375

-26,175

-28,472

-28,526

-27,906

-26,182

-23,349

-21,377

-7,802

-7,600

-5,091

-3,342

-12,678

0

0

0

Weighted Average Shares Outstanding, basic and diluted

5,560

-39,809

19,585

19,585

2,627

-51,363

17,824

17,674

17,674

17,679

17,574

17,207

16,636

16,596

16,582

16,561

16,507

16,490

16,466

16,449

16,448

11,536

240

240

240

233

Foreign currency translation adjustment

-

-

-6

-4

-

-1

5

5

8

6

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

Unrealized gain on available-for-sale investments

-

-

-

-

-

20

6

3

-12

-20

-15

-17

-12

11

2

7

12

-5

24

-2

0

-

0

0

-

0

Comprehensive loss

-

-

-18,646

-21,615

-

-20,710

-21,010

-28,810

-29,551

-29,978

-31,390

-26,192

-28,484

-28,515

-27,904

-26,175

-23,337

-21,382

-20,192

-17,398

0

-

0

0

-

0

Net loss

-23,524

-14,992

-13,638

-16,612

-16,176

-20,729

-21,021

-28,818

-29,547

-29,964

-31,375

-26,175

-28,472

-28,526

-27,906

-26,182

-23,349

-21,377

-7,802

-7,600

-5,091

-3,342

-12,678

0

0

0

Accretion of convertible preferred stock to redemption value

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accretion of convertible preferred stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

Accretion of redeemable convertible preferred stock to redemption value

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

6,353

2,672

0

0

0

Net loss attributable to common stockholders

-

-

-18,641

-21,615

-

-

-21,021

-35,565

-36,294

-36,711

-38,122

-26,175

-28,472

-28,526

-27,906

-26,182

-23,349

-21,377

-8,469

-10,544

-9,932

-9,695

-19,904

0

0

0

Net loss per share, basic and diluted

-1.81

-29.22

-0.08

-0.27

-0.58

-44.93

-0.25

-0.28

-0.34

-0.33

-1.08

-0.33

-0.39

-0.41

-0.43

-0.48

-0.40

-0.38

-0.33

-0.31

-0.28

64.48

-31.00

-18.55

-18.09

-15.60

Allocated share-based compensation

-

-

1,759

2,567

-

-

3,415

3,258

3,203

3,227

3,303

3,243

3,322

3,343

3,169

3,093

2,623

2,164

1,719

1,293

849

459

0

0

0

-

Realized losses from forward foreign currency contracts

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-46

-42

-46

-52

0

0

0

-

-

-

-

-

Unrealized gains (losses) from forward foreign currency contracts

-

-

-

-

-

-

-

-

-

-

-

-

-

-

16

-300

-359

-537

0

0

0

-

-

-

-

-

Total

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-30

-342

-405

-589

0

0

0

-

-

-

-

-

Comprehensive loss

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

Research and Development Expense [Member]
Allocated share-based compensation

-

-

498

822

-

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

General and Administrative Expense [Member]
Allocated share-based compensation

-

-

1,261

1,745

-

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-